SEC Filings
Nektar Expects Its $952.9 Million Cash Pile To Last Beyond Initial Trial Results
Research spending rose as the company advanced its lead drug, with initial late-stage dermatitis results expected in summer 2028.
Nektar Therapeutics (NKTR) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Research spending rose as the company advanced its lead drug, with initial late-stage dermatitis results expected in summer 2028.
Earnings
Treatment-withdrawal results due in the first quarter of 2027 will help test how long the experimental drug's benefits last.
SEC Filings
The drug developer held $952.9 million in cash and investments as it advanced rezpegaldesleukin into late-stage testing.
SEC Filings
The September 30 holding puts State Street alongside shareholders backing Nektar's late-stage eczema drug development.